

IBC Meeting Minutes

Cleveland Clinic Florida Research and Innovation Center

Date: February 19, 2026	Location: Zoom
IBC Member Attendance:	
<input checked="" type="checkbox"/> McDonald, Christine (IBC Chair) <input type="checkbox"/> Li, Kun <input checked="" type="checkbox"/> Such, Kimberly <input checked="" type="checkbox"/> Champer, Dylan (BSO) <input checked="" type="checkbox"/> Hajjar, Adeline <input type="checkbox"/> Judd, Leslie <input checked="" type="checkbox"/> Tavakoli, Sara <input checked="" type="checkbox"/> O'Connor, Christine <input checked="" type="checkbox"/> Doud, Melissa <input checked="" type="checkbox"/> Stolley, Michael	
<i>Guests: Amanda Dragan*, Abby Bifano*, Anthony Santilli*, Jennifer Veillette*, Nikki Meyer*, Ashley Barth*, Daniel Blaz*</i>	
<i>*Cleveland Clinic Main Campus</i>	
Call To Order: 2:34 pm	Adjourn: 4:02 pm

I. Review of January 15th, 2026 Meeting Minutes

Committee Comments: None			
Motion: Approval	For: 5	Against: 0	Abstain: 3

II. Administrative Business

- a. Committee presented with Expedited Review items and personnel additions.
- b. Lab Audits: Members were presented with Annual Lab Audits occurring during the month of January 2026. No major deficiencies were identified.
- c. IBC Members were updated on the approval of the Influenza Guidance Document.
- d. IBC Members were informed of an incident with the security system that occurred in fall of 2025 and was rectified in January 2026.
- e. IBC Members were updated on the results of the inventory audit conducted by FRIC's Responsible and Alternate Responsible Officials of the ABSL-3 infectious agents.
- f. IBC Members were presented the results from the Annual Performance Verification (APV) of the ABSL/BSL-3 done in January 2026.
- g. IBC Members were informed that the CDC will be at FRIC on March 5th to conduct an audit as part of the import permit program.

III. Non-Clinical Research:

a. New Applications:

Basic Research Application # 1	Protocol ID: Application #1	PI: Lee	Biosafety Level: BSL1, BSL2, ABSL1, ABSL2, Toxin	NIH Cat.: III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-a, III-D-4-b	
Project Titles: Sex-based differences in glioblastoma tumor microenvironment					
Associated Grant Numbers: Non-NIH Funded					
Protocol Summary: <ul style="list-style-type: none"> • Generation of replication defective lentivirus, transduction of tissue culture cells and administration of transduced cells in vivo; Administration of plasmid in vivo; Administration of Diphtheria Toxin (DT) in vivo; Human-derived materials. 					
Function/Nature of Recombinant Genes to be Expressed: <input type="checkbox"/> N/A <input type="checkbox"/> Oncogene <input type="checkbox"/> Tumor Suppressor Gene <input type="checkbox"/> Structural <input checked="" type="checkbox"/> Signaling <input type="checkbox"/> Antimicrobial <input type="checkbox"/> Immunomodulatory <input type="checkbox"/> Toxin <input type="checkbox"/> Antibiotic Resistance <input checked="" type="checkbox"/> Reporters <input type="checkbox"/> Other					
Species of Recombinant Genes to be Expressed: <input type="checkbox"/> N/A <input type="checkbox"/> Human <input type="checkbox"/> Murine <input type="checkbox"/> Rat <input type="checkbox"/> Bacterial <input type="checkbox"/> Viral <input checked="" type="checkbox"/> Other					
Risk Assessment Discussion: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			Facilities, Procedures, and Safety Practices Reviewed (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Committee Comments: <ul style="list-style-type: none"> • Administrative edits • Reference applicable SOP for working with diphtheria toxin. • Clarify vector information in the appendix. 					
PI/Supervisor Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			Handler Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Motion: Approved with Administrative Revisions	For: 8	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0

b. Renewals:

Basic Research Renewal #1	Protocol ID: FLIBC019	PI: Ross	Biosafety Level: BSL-2, BSL-2+, ABSL-2	NIH Cat.: III-D-3-a, III-D-4-b, III-D-7, III-E	
Project Titles: Influenza virus neutralization					

Associated Grant Numbers: Non-NIH Funding					
Summary of Approved Items: Propagation of Influenza A & B viral strains and generation of recombinant Influenza A & B viral strains; transduction of tissue culture cells; administration to mice and ferrets; Generation of lentiviral particles to produce influenza pseudovirus, <i>in vivo</i> administration; Human-derived materials.					
<u>Function/Nature of Recombinant Genes to be Expressed:</u> <input type="checkbox"/> N/A <input type="checkbox"/> Oncogene <input type="checkbox"/> Tumor Suppressor Gene <input checked="" type="checkbox"/> Structural <input checked="" type="checkbox"/> Signaling <input type="checkbox"/> Antimicrobial <input type="checkbox"/> Immunomodulatory <input type="checkbox"/> Toxin <input type="checkbox"/> Antibiotic Resistance <input type="checkbox"/> Reporters <input type="checkbox"/> Other					
<u>Species of Recombinant Genes to be Expressed:</u> <input checked="" type="checkbox"/> N/A <input type="checkbox"/> Human <input type="checkbox"/> Murine <input type="checkbox"/> Rat <input type="checkbox"/> Bacterial <input checked="" type="checkbox"/> Viral <input type="checkbox"/> Other					
Risk Assessment Discussion: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			Facilities, Procedures, and Safety Practices Reviewed (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Committee Comments: <ul style="list-style-type: none"> • Administrative edits • Addition of appendix for usage of equipment • Clarifications on handling of sharps 					
PI/Supervisor Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			Handler Training (Y/N): <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Motion: Approved with Administrative Revisions	For: 8	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0

c. Amendments:

Basic Research Amendment # 1	Protocol ID: FLIBC021	PI: Sautto	Biosafety Level: BSL-1, BSL-2+, ABSL-2	NIH Cat.: III-E, III-D-1-a, III-D-2-a
Project Titles: Influenza and hepatitis C virus neutralization				
Associated Grant Numbers: Non-NIH Funding				
Summary of Approved Items: Propagation and generation of Influenza A & B viral strains and recombinant Hepatitis C Virus, virus like particles / pseudoparticles; Transduction of tissue culture cells; Generation of phagemid and retroviral particles, transduction of cells in-vitro, administration of Influenza A & B viral strains, plasmid DNA, <i>in vivo</i> administration of recombinant proteins; Recombinant and Non-Recombinant Respiratory syncytial virus and human metapneumovirus for in vitro				

and *in vivo* experiments; Propagation of SARS-CoV-2, *in vivo* administration of SARS-CoV-2, human-derived materials.

Requested Additions/Changes:

- Measles virus and corresponding neutralization assay, vaccine vector for HCV, generation of Nipah pseudovirus and corresponding assay.

Function/Nature of Recombinant Genes to be Expressed:

N/A Oncogene Tumor Suppressor Gene Structural Signaling Antimicrobial
 Immunomodulatory Toxin Antibiotic Resistance Reporters Other

Species of Recombinant Genes to be Expressed:

N/A Human Murine Rat Bacterial Viral Other

Risk Assessment Discussion:

Yes No

Facilities, Procedures, and Safety Practices Reviewed (Y/N):

Yes No

Committee Comments:

- Clarification of new risks
- Add description of new vectors for risk assessment
- Indicate room where proposed work will be performed
- Administrative edits

PI/Supervisor Training (Y/N):

Yes No

Handler Training (Y/N):

Yes No

Motion: Tabled, PI to address comments and resubmit	For: 8	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0
---	------------------	----------------------	----------------------	---------------------	--------------------------

IV. Updated SOPs:

SOP a: L.SOP.405.03 Select Agent Inventory	Comments: Administrative edits				
Motion: Approved with Administrative Revisions	For: 8	Against: 0	Abstain: 0	Recuse: 0	

SOP b: L.SOP.400.10 - BSL-3 Training Procedures	Comments: Administrative edits				
Motion: Approved with Administrative Revisions	For: 8	Against: 0	Abstain: 0	Recuse: 0	

SOP c: L.SOP.300.03 - Sharps - Safe Handling and Disposal	Comments: None				
Motion: Approved	For: 8	Against: 0	Abstain: 0	Recuse: 0	

SOP d: L.PLAN.MED.13 BSL-3 Medical Surveillance Plan	Comments: Administrative edits			
Motion: Approved with Administrative Revisions	For: 8	Against: 0	Abstain: 0	Recuse: 0

SOP e: L.PLAN.APP.03 Agent Hazard Information	Comments: Administrative edits			
Motion: Approved with Administrative Revisions	For: 8	Against: 0	Abstain: 0	Recuse: 0

SOP f: R.SOP.500.02 - Pertussis Toxin	Comments: Administrative edits			
Motion: Approved with Administrative Revisions	For: 6	Against: 0	Abstain: 0	Recuse: 2

SOP g: R.SOP.501.01 - Cholera Toxin	Comments: Contingency item, Veterinary review of language pertaining to disinfection in the vivarium.			
Motion: Approved with Contingency	For: 7	Against: 0	Abstain: 0	Recuse: 1

SOP h: R.SOP.502.01 - Diphtheria Toxin	Comments: Administrative edits			
Motion: Approved with Administrative Revisions	For: 6	Against: 0	Abstain: 0	Recuse: 2

SOP i: R.SOP.503.01 – Tetrodotoxin	Comments: Administrative edits			
Motion: Approved with Administrative Revisions	For: 6	Against: 0	Abstain: 0	Recuse: 2